This trial established that the combination of the BRAF inhibitor encorafenib with EGFR monoclonal antibody cetuximab was superior to chemotherapy in pretreated patients with metastatic colorectal cancer bearing BRAF V600E mutations. The gene discussed is EGFR; the disease is metastatic colorectal cancer.